Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Alpha Emitter Market Growth, Trends and Forecasts Through 2019-2024 - ResearchAndMarkets.com

March 19, 2019

DUBLIN--(BUSINESS WIRE)--Mar 19, 2019--The “Alpha Emitter Market - Growth, Trends, and Forecast (2019 - 2024)” report has been added to ResearchAndMarkets.com’s offering.

The global alpha emitter market was valued at USD 506.5 million in 2018, and it is estimated to be valued at USD 3,302.99 million by 2024 while witnessing a CAGR of 36.69% over the forecast period of 2019-2024.

Certain factors that are driving the market growth include increased awareness about the potential benefits of targeted alpha therapy, and the growing number of patients with cardiac and cancer ailments.

Targeted anticancer or alpha therapy (TAT) is gaining popularity with the increasing prevalence of cancer and cardiovascular diseases. Consumers are now increasingly aware of the potential benefits of targeted therapies to cure such ailments.

Furthermore, radioimmunotherapy with short-ranged and high-efficiency -particles is a striking and promising treatment approach. -particles have an advantage in targeted therapy because of their exceptionally high cell-killing ability.

However, regulatory requirements pose a hurdle to translational research and clinical investigations. For instance, in the United States, all pharmacologic agents, including diagnostic radiopharmaceuticals and radiotherapeutics, undergo regulatory oversight by the FDA. Similarly, radiopharmaceuticals face additional scrutiny and undergo unique regulatory and approval pathways, across the world.

Key Market Trends

Medical Application in Ovarian Cancer is Expected to Observe the Highest Growth Rate over the Forecast Period

The ovarian cancer segment in the alpha emitter market is expected to witness the highest CAGR of 35.63% during the forecast period.

The growth rate is attributed to an increasing number of new diagnosis cases. As per the estimates of the American Cancer Society, in 2018, around 22,240 women were expected to receive a new diagnosis of ovarian cancer, and about 14,070 women would die from ovarian cancer.

Ovarian cancer uses radioimmunotherapy as locally injected adjuvant therapy. Trials have evaluated the practice of complete abdominal or moving-strip external-beam radiotherapy (EBRT) or non-specific i.p. radiotherapy, with colloid preparations of Au-198 or P-32 as adjuvant therapies.

Moreover, the adoption of targeted alpha therapy with higher LET and shorter wavelengths has been promising in the treatment process. This trend is expected to gain traction in the near future.

In addition, a recent Phase I clinical trial involving At-211-MX35 F (ab) showed significant efficacy, as therapeutic doses reached their targets in patients with ovarian cancer.

North America Dominates the Market and is Expected to do the same during the Forecast Period

North America currently dominates the alpha emitter market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the fact that the increase in cardiac and neurological chronic diseases is the major driving factor for the market growth in the region. For instance, 223RaCl2 (Xofigo) is the first alpha-emitting radioisotope to gain registration in the United States for palliative therapy of prostate cancer bone metastases through indirect physiological targeting.

Moreover, according to the National Cancer Institute, the number of new cases of melanoma was 21.8 per 100,000 men and women, per year. Similarly, the rising prevalence of cancer is making it imperative for the healthcare professionals across Canada to increase the radiotherapy utilization for cancer treatment. This is directly affecting the growth of the alpha emitter market in the country.

Competitive Landscape

The global alpha emitter market is less competitive and consists of very few major players. Companies, like IBA Radiopharma Solutions, Bayer, Alpha Tau Medical, Actinium Pharmaceutical, Telix Pharmaceuticals, RadioMedix, and Fusion Pharmaceuticals hold the substantial market share in the global alpha emitter market.

A number of developments have been taking place in the market over recent years. For example, in November 2017, Actinium Pharmaceuticals launched the AWE Program, aka Actinium Warhead Enabling Program, to enable collaborations based on its Actinium-225 Technology Platform.

Whereas, in November 2017, Alpha Tau Medical entered a collaboration with IRST Italy to treat its first cancer patients. This is significant progress toward international expansion. This is also expected to enable the availability of Alpha DaRT radiotherapy all across Europe, Asia, as well as the United States.

Topics Covered

1 Introduction

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Dynamics

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increased Awareness About the Potential Benefits of Targeted Alpha Therapy

4.2.2 Increasing Number of Patients with Cardiac and Cancer Ailments

4.3 Market Restraints

4.3.1 Short Half-life of Radiopharmaceuticals

4.3.2 Stringent Regulatory Framework and Reimbursement Issues

4.3.3 Need for High Capital Investment

4.4 Porter’s Five Forces Analysis

5 Market Segmentation

5.1 Type of Radionuclide

5.1.1 Terbium (Tb-149)

5.1.2 Astatine (At-211)

5.1.3 Bismuth (Bi-212)

5.1.4 Actinium (Ac-225)

5.1.5 Radium (Ra-223)

5.1.6 Lead (Pb-212)

5.1.7 Bismuth (Bi -213)

5.2 Medical Application

5.2.1 Glioma

5.2.2 Melanoma

5.2.3 Pancreatic Cancer

5.2.4 Ovarian Cancer

5.2.5 Thyroid

5.2.6 Bone Metastasis

5.2.7 Lymphoma

5.2.8 Endocrine Tumors

5.2.9 Other Medical Applications

5.3 Geography

5.3.1 North America

5.3.2 Europe

5.3.3 Asia-Pacific

5.3.4 Middle East & Africa

5.3.5 South America

6 Competitive Landscape

6.1 Company Profiles

6.1.1 Actinium Pharmaceutical Inc.

6.1.2 Alpha Tau Medical Ltd.

6.1.3 Bayer AG

6.1.4 Fusion Pharmaceuticals

6.1.5 IBA Radiopharma Solutions

6.1.6 RadioMedix Inc.

6.1.7 Telix Pharmaceuticals Ltd.

7 Market Opportunities and Future Trends

For more information about this report visit https://www.researchandmarkets.com/research/zh6z6c/global_alpha?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190319005446/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Nuclear Medicine and Radiopharmacology



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/19/2019 07:38 AM/DISC: 03/19/2019 07:38 AM